Using semi-conductor technologies and micro-fluidics, the new Dynamic Multi-Analyte technology (DMAT) analyzes several biomarkers at the same time, thus enabling accelerated development of multiplex assays.

In addition, the platform reduces hands-on time and allows users to perform bioassays cost-effectively, while ensuring optimal accuracy.

Biocartis CEO Greg Parekh said the technology will accelerate the conversion of biomarker discoveries into clinical practice and will help scientists to discover several personalized medicines.

"DMAT is complementary with protein biomarker discovery and next generation sequencing, because the ease of use, sensitivity and accuracy enables rapid validation of new biomarkers initially identified on these other platforms," Parekh added.